Loading…
Enanta Pharmaceuticals, Inc. is projected to rise to $14.23 by 2027, a +13% move from its current price of $12.60. ENTA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $12.31 | $12.60 | $12.89 | -0.02% |
| Aug 4 | $12.19 | $12.60 | $13.02 | -0.03% |
| Aug 5 | $12.10 | $12.59 | $13.11 | -0.05% |
| Aug 6 | $12.02 | $12.59 | $13.19 | -0.07% |
| Aug 7 | $11.95 | $12.59 | $13.26 | -0.09% |
| Aug 8 | $11.89 | $12.59 | $13.32 | -0.10% |
| Aug 9 | $11.83 | $12.58 | $13.38 | -0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.83 | $12.58 | $13.38 | -0.12% |
| Week 2 | $11.52 | $12.57 | $13.71 | -0.24% |
| Week 3 | $11.29 | $12.55 | $13.97 | -0.36% |
| Week 4 | $11.09 | $12.54 | $14.18 | -0.48% |
| Week 5 | $10.92 | $12.52 | $14.37 | -0.60% |
| Week 6 | $10.76 | $12.51 | $14.54 | -0.72% |
| Week 7 | $10.62 | $12.49 | $14.70 | -0.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Enanta Pharmaceuticals, Inc. is a biotechnology company that discovers and develops small molecule drugs for virology and immunology indications.
Its product pipeline includes EDP-514 in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which are in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.
The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
The current price of ENTA is $13.23. The stock has a market capitalization of $384.71M and ranks 3276.
In the near term, the technical picture is NEUTRAL with RSI(14) at 50, the SMA50 at $13.43, and the SMA200 at $13.20.
Key price levels include a support at $11.07 and a resistance at $15.11, and the 30-day price range spans from $11.21 to $15.62.
The longer-run price outlook is bullish in the forecast, with the 2030 average price at $22.04 and the 2050 average at $83.46, and ROIs of 66.6% by 2030 and 530.8% by 2050.
A major floor 14.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.2% away) — a key level to hold.
The nearest ceiling, 19.9% above — a clean break opens room to run.
A major ceiling 27.4% above — clearing it would confirm fresh momentum.
Key ENTA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ENTA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.68 | Sell | $12.73 | Sell |
| MA 10 | $12.88 | Sell | $12.89 | Sell |
| MA 20 | $13.34 | Sell | $13.12 | Sell |
| MA 50 | $13.08 | Sell | $13.27 | Sell |
| MA 100 | $13.35 | Sell | $13.26 | Sell |
| MA 200 | $13.31 | Sell | $12.68 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.67 | Neutral |
| Stoch RSI (14) | 28.03 | Neutral |
| CCI (20) | -94.33 | Neutral |
| Williams %R (14) | -88.37 | Info |
| MACD (12,26,9) | -0.11 | Sell |
| ROC (12) | -4.76 | Sell |
| Bollinger %B (20,2) | 0.20 | Neutral |
| Stochastic %K (14) | 11.63 | Buy |
| TRIX (15) | -0.09 | Sell |
| Awesome (5,34) | -0.71 | Sell |
| Ultimate (7,14,28) | 37.24 | Neutral |
| Momentum (10) | -1.14 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 12.60 | Sell |
| ADX (14) | 14.24 | Neutral |
| ATR (14) | 0.31 | Info |
The 30-day technical picture is NEUTRAL.
RSI(14) is 50, indicating neutral momentum. The price is trading between moving averages: the 50-day SMA is $13.43 and the 200-day SMA is $13.20. The price sits just below the 50-day SMA and just above the 200-day SMA, reflecting a mixed near-term posture.
Within the 30-day range, the low is $11.21 and the high is $15.62.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.07 | $12.60 | $15.08 | 0% | Neutral | |
| $11.50 | $14.23 | $18.51 | +13% | Neutral | |
| $13.91 | $17.62 | $23.69 | +40% | Bullish | |
| $14.83 | $19.16 | $26.42 | +52% | Bullish | |
| $15.77 | $20.72 | $29.19 | +64% | Bullish | |
| $16.05 | $21.41 | $30.74 | +70% | Bullish | |
| $16.54 | $22.39 | $32.69 | +78% | Bullish | |
| $17.56 | $24.09 | $35.71 | +91% | Bullish | |
| $18.81 | $26.13 | $39.29 | +107% | Bullish | |
| $22.05 | $31.01 | $47.24 | +146% | Bullish | |
| $27.12 | $40.28 | $64.84 | +220% | Bullish | |
| $49.67 | $80.90 | $141.18 | +542% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $11.07 | $12.60 | $14.95 | +0.00% |
| September 2026 | $10.40 | $12.25 | $14.79 | -2.79% |
| October 2026 | $10.47 | $12.40 | $15.12 | +1.27% |
| November 2026 | $10.52 | $12.52 | $15.37 | +0.92% |
| December 2026 | $10.20 | $12.19 | $15.08 | -2.59% |
Click any year to see its month-by-month ENTA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ENTA to range from $11.07 to $15.08 through 2026. The $12.60 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ENTA price prediction for 2027 points to an average of $14.23 (low $11.50, high $18.51) — a potential gain of +13% on today's $12.60. Price action looks broadly range-bound.
In 2028, ENTA is projected to trade between $13.91 and $23.69, averaging $17.62 — a potential gain of +40% from today's $12.60. That is up +24% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Enanta Pharmaceuticals, Inc.'s 2029 outlook centres on $19.16, within a $14.83 to $26.42 range. That is up +9% on the projected 2028 average. That marks a +52% change versus current levels. Momentum favours further upside here.
By 2030, ENTA could reach as high as $29.19, with a base case around $20.72 and support toward $15.77 — roughly +64% from $12.60. Buyers look set to stay in control over this stretch.
Expect ENTA to range from $16.05 to $30.74 through 2031. The $21.41 average target implies a +70% move from current prices. That is up +3% on the projected 2030 average. Momentum favours further upside here.
The ENTA price prediction for 2032 points to an average of $22.39 (low $16.54, high $32.69) — a potential gain of +78% on today's $12.60. Buyers look set to stay in control over this stretch.
In 2033, ENTA is projected to trade between $17.56 and $35.71, averaging $24.09 — a potential gain of +91% from today's $12.60. That is up +8% on the projected 2032 average. Momentum favours further upside here.
Enanta Pharmaceuticals, Inc.'s 2034 outlook centres on $26.13, within a $18.81 to $39.29 range. That is up +9% on the projected 2033 average. That marks a +107% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ENTA could reach as high as $47.24, with a base case around $31.01 and support toward $22.05 — roughly +146% from $12.60. Momentum favours further upside here.
Expect ENTA to range from $27.12 to $64.84 through 2040. The $40.28 average target implies a +220% move from current prices. That is up +30% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ENTA price prediction for 2050 points to an average of $80.90 (low $49.67, high $141.18) — a potential gain of +542% on today's $12.60. Momentum favours further upside here.
Investing $1,000 in ENTA today (≈ 79.365079 ENTA) could be worth
$6,420.35
+$5,420.35 (+542%) by 2050 · US Dollar
Based on the average projected ENTA price of $80.9 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ENTAwould be worth at today's price.
$1,000 invested in ENTA on Jul 31, 2025 (≈ 131.926123 ENTA) would be worth
$1,662.27
+$662.27 (+66.2%) today · 1.66× · US Dollar
Based on a ENTA entry price of $7.58 vs. today's $12.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.78 | $985.92 | -1.4% |
| 1 month ago | $14.77 | $853.08 | -14.7% |
| 3 months ago | $14.35 | $878.05 | -12.2% |
| 6 months ago | $13.19 | $955.27 | -4.5% |
| 1 year ago | $7.58 | $1,662.27 | +66.2% |
| All time (5.0y) ago | $43.1 | $292.34 | -70.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ENTA forecast.
Our base-case forecast reaches $25.00 around 2034.
Implied market cap at $25.00: $726.96M
The multi-year forecast shows a steady upward trajectory starting in the late 2020s, with 2026 to 2035 results and then substantial gains by 2040 and 2050.
For 2026 the min, avg, and max are $11.07, $13.23, and $15.70 respectively, with ROI 0 and sentiment NEUTRAL. The 2027 forecast is $12.22 (min), $15.24 (avg), and $20.04 (max) with ROI 15.2 and sentiment NEUTRAL. The path accelerates in subsequent years, with 2028 at $14.62/$18.71/$25.47 (ROI 41.4) and 2029 at $15.25/$19.93/$27.88 (ROI 50.6).
The 2030 forecast is $16.56 (min), $22.04 (avg), and $31.55 (max) with ROI 66.6 and sentiment BULLISH. The 2031 forecast is $16.56/$22.42/$32.74 (ROI 69.5), 2032 is $16.80/$23.10/$34.33 (ROI 74.6), and 2033 is $18.22/$25.43/$38.42 (ROI 92.2).
2034 is $19.09/$27.02/$41.44 (ROI 104.2), and 2035 is $22.57/$32.37/$50.34 (ROI 144.7). The forecast grows further to 2040 with $27.13/$41.34/$68.15 (ROI 212.5) and culminates in 2050 at $49.42/$83.46/$149.82 (ROI 530.8). Sentiment shifts from NEUTRAL in 2026–2027 to BULLISH from 2028 onward. These figures are estimates, not guarantees.
Overall, the longer-term outlook points to meaningful upside with a bullish trajectory, but execution risk and market dynamics can affect actual results.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $22.04, with a low of $16.56 and a high of $31.55. The expected ROI is 66.6%, and the sentiment is BULLISH.
Forecasts show a path of rising averages into 2030 and beyond, with 2030 avg $22.04 (ROI 66.6%), 2040 avg $41.34 (ROI 212.5%), and 2050 avg $83.46 (ROI 530.8%), and sentiment turning BULLISH from 2028 onward. These are estimates, not guarantees.
Yes. The 2026 forecast maximum is $15.70, and the 2027 maximum is $20.04.
The 2027 forecast shows an average price of $15.24, a low of $12.22, a high of $20.04, and a ROI of 15.2%, with sentiment NEUTRAL.
The 2050 forecast shows an average price of $83.46, a low of $49.42, a high of $149.82, and a ROI of 530.8%, with sentiment BULLISH.
Enanta Pharmaceuticals, Inc. Community Discussion
0Share your Enanta Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.